Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma
Targeted treatment of USC using the biomarker TROP2 represents a significant opportunity for further treatment options for patients already resistant to other lines of treatment. In this study, we present data showing preclinical evidence of effectiveness of this biomarker-targeted therapy in USC.
Authors
- Cem Demirkiran (ORCID: https://orcid.org/0000-0002-7073-2819)
- Michelle Greenman (ORCID: https://orcid.org/0000-0003-1809-1468)
- Alessandro D. Santin (ORCID: https://orcid.org/0000-0003-4724-9738)
- Katyayani Papatla (ORCID: https://orcid.org/0000-0003-3372-0402)
- Elena Ratner (ORCID: https://orcid.org/0000-0002-6277-6002)
- Stefania Bellone (ORCID: https://orcid.org/0000-0001-5909-5292)
- Yang Yang‐Hartwich (ORCID: https://orcid.org/0000-0002-0522-9053)
- Namrata Sethi (ORCID: https://orcid.org/0000-0003-1586-3338)
- Victoria M. Ettorre (ORCID: https://orcid.org/0000-0002-2439-2534)
- Blair McNamara
- Tobias M.P. Hartwich (ORCID: https://orcid.org/0000-0002-2854-2894)
- Niccolò G. Santin (ORCID: https://orcid.org/0009-0001-2669-0973)
Institutions
- Yale University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0057
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Gilead Sciences
- Discovery To Cure
- Daiichi-Sankyo
- Eisai
- National Institutes of Health
- Stand Up To Cancer
- National Cancer Institute